These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease. Stepanian A; Ribba AS; Lavergne JM; Fressinaud E; Juhan-Vague I; Mazurier C; Girma JP; Meyer D Br J Haematol; 2003 Feb; 120(4):643-51. PubMed ID: 12588351 [TBL] [Abstract][Full Text] [Related]
23. von Willebrand factor self-association is regulated by the shear-dependent unfolding of the A2 domain. Zhang C; Kelkar A; Neelamegham S Blood Adv; 2019 Apr; 3(7):957-968. PubMed ID: 30936056 [TBL] [Abstract][Full Text] [Related]
24. Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences. Randi AM; Rabinowitz I; Mancuso DJ; Mannucci PM; Sadler JE J Clin Invest; 1991 Apr; 87(4):1220-6. PubMed ID: 2010538 [TBL] [Abstract][Full Text] [Related]
25. Altered von Willebrand factor subunit proteolysis and multimer processing associated with the Cys2362Phe mutation in the B2 domain. Casonato A; De Marco L; Gallinaro L; Sztukowska M; Mazzuccato M; Battiston M; Pagnan A; Ruggeri ZM Thromb Haemost; 2007 Apr; 97(4):527-33. PubMed ID: 17393013 [TBL] [Abstract][Full Text] [Related]
26. Internal Tensile Force and A2 Domain Unfolding of von Willebrand Factor Multimers in Shear Flow. Morabito M; Dong C; Wei W; Cheng X; Zhang XF; Oztekin A; Webb E Biophys J; 2018 Nov; 115(10):1860-1871. PubMed ID: 30287111 [TBL] [Abstract][Full Text] [Related]
27. Calcium stabilizes the von Willebrand factor A2 domain by promoting refolding. Xu AJ; Springer TA Proc Natl Acad Sci U S A; 2012 Mar; 109(10):3742-7. PubMed ID: 22357761 [TBL] [Abstract][Full Text] [Related]
28. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets. Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222 [TBL] [Abstract][Full Text] [Related]
29. Destabilization of the von Willebrand factor A2 domain under oxidizing conditions investigated by molecular dynamics simulations. Interlandi G PLoS One; 2018; 13(9):e0203675. PubMed ID: 30222754 [TBL] [Abstract][Full Text] [Related]
30. Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease. Schneppenheim R; Brassard J; Krey S; Budde U; Kunicki TJ; Holmberg L; Ware J; Ruggeri ZM Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3581-6. PubMed ID: 8622978 [TBL] [Abstract][Full Text] [Related]
31. Force-induced on-rate switching and modulation by mutations in gain-of-function von Willebrand diseases. Kim J; Hudson NE; Springer TA Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4648-53. PubMed ID: 25810255 [TBL] [Abstract][Full Text] [Related]
32. A novel calcium-binding site of von Willebrand factor A2 domain regulates its cleavage by ADAMTS13. Zhou M; Dong X; Baldauf C; Chen H; Zhou Y; Springer TA; Luo X; Zhong C; Gräter F; Ding J Blood; 2011 Apr; 117(17):4623-31. PubMed ID: 21385852 [TBL] [Abstract][Full Text] [Related]
33. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. Dumas JJ; Kumar R; McDonagh T; Sullivan F; Stahl ML; Somers WS; Mosyak L J Biol Chem; 2004 May; 279(22):23327-34. PubMed ID: 15039442 [TBL] [Abstract][Full Text] [Related]
35. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Nishio K; Anderson PJ; Zheng XL; Sadler JE Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10578-83. PubMed ID: 15249683 [TBL] [Abstract][Full Text] [Related]
36. Structure and function of snake venom toxins interacting with human von Willebrand factor. Matsui T; Hamako J Toxicon; 2005 Jun; 45(8):1075-87. PubMed ID: 15922776 [TBL] [Abstract][Full Text] [Related]
37. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management. Michiels JJ; van Vliet HH Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362 [TBL] [Abstract][Full Text] [Related]
38. Mutational Constraints on Local Unfolding Inhibit the Rheological Adaptation of von Willebrand Factor. Tischer A; Campbell JC; Machha VR; Moon-Tasson L; Benson LM; Sankaran B; Kim C; Auton M J Biol Chem; 2016 Feb; 291(8):3848-59. PubMed ID: 26677223 [TBL] [Abstract][Full Text] [Related]
39. The mutation Arg (53)----Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor. Jorieux S; Tuley EA; Gaucher C; Mazurier C; Sadler JE Blood; 1992 Feb; 79(3):563-7. PubMed ID: 1732004 [TBL] [Abstract][Full Text] [Related]
40. Differential effects of the loss of intrachain- versus interchain-disulfide bonds in the cystine-knot domain of von Willebrand factor on the clinical phenotype of von Willebrand disease. Tjernberg P; Vos HL; Spaargaren-van Riel CC; Luken BM; Voorberg J; Bertina RM; Eikenboom JC Thromb Haemost; 2006 Dec; 96(6):717-24. PubMed ID: 17139364 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]